Belite Bio

Historical price data

Belite Bio is a publicly traded clinical-stage biopharmaceutical company focused on advancing novel therapeutics for retinal degenerative eye diseases with significant unmet medical needs. Their lead candidate Tinlarebant, developed from their proprietary RBP4 IP portfolio, is currently in multiple Phase 3 trials for Geographic Atrophy and Stargardt disease, with breakthrough therapy and orphan drug designations. The company has expanded their pipeline to include treatments for liver disease and diabetes, leveraging their core RBP4 platform technology.

Proprietary RBP4 (Retinol Binding Protein 4) intellectual property portfolio targeting toxic accumulation in the eye and metabolic pathways associated with vitamin A transport and metabolism.

7 drugs in pipeline, 3 in Phase 3

Competes with Apellis Pharmaceuticals and other companies in Geographic Atrophy treatment, but benefits from oral administration advantage and strong regulatory positioning. In Stargardt disease, limited competition provides clearer market opportunity.